AZILECT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5532415 | TEVA | R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof |
Jul, 2013
(10 years ago) | |
| US7815942 | TEVA | Rasagiline formulations of improved content uniformity |
Aug, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6126968 | TEVA | Stable compositions containing N-propargyl-1-aminoindan |
Sep, 2016
(7 years ago) | |
| US5453446 | TEVA | Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease. |
Feb, 2017
(7 years ago) | |
| US7572834 | TEVA | Rasagiline formulations and processes for their preparation |
Dec, 2026
(2 years from now) | |
Azilect is owned by Teva.
Azilect contains Rasagiline Mesylate.
Azilect has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Azilect are:
- US6126968
- US5453446
- US5532415
Azilect was authorised for market use on 16 May, 2006.
Azilect is available in tablet;oral dosage forms.
Azilect can be used as treatment of parkinson's disease.
The generics of Azilect are possible to be released after 27 August, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-685) | May 29, 2017 |
Drugs and Companies using RASAGILINE MESYLATE ingredient
Market Authorisation Date: 16 May, 2006
Treatment: Treatment of parkinson's disease
Dosage: TABLET;ORAL
More Information on Dosage
AZILECT family patents
